GlassScriptPhysician profile
Andrew S Chun
NPI 1497930986
$4,357.48
in general payments reported to CMS, 2019-2025
23 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $138 · 2021: $220 · 2022: $1,928 · 2023: $769 · 2024: $724 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,739.44 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $671.05 | 2021-2025 | Acthar |
| Oyster Point Pharma, INC. | $474.88 | 2022-2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $254.15 | 2019-2025 | |
| Dompe US, INC. | $208.39 | 2021-2024 | Oxervate |
| Abbvie INC. | $193.21 | 2022-2023 | Durysta, Vuity, Lumigan |
| Novartis Pharmaceuticals Corporation | $112.02 | 2021-2022 | |
| Alcon Vision LLC | $103.87 | 2023-2025 | Rocklatan, Eysuvis, Clareon |
| Aerie Pharmaceuticals, INC. | $92.85 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $74.99 | 2022-2023 | Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $63.75 | 2024-2025 | Xdemvy |
| Rxsight INC | $62.06 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Allergan, INC. | $58.55 | 2020-2022 | |
| Harrow Eye, LLC | $38.39 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $36.01 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $30.58 | 2023-2025 | Tearcare System |
| Astellas Pharma US INC | $25.87 | 2024 | Izervay |
| Glaukos Corporation | $24.05 | 2024 | Idose |
| Shire North American Group INC | $22.58 | 2019 | |
| Rayner Intraocular Lenses Limited | $21.31 | 2024 | Omidria |
| Eyevance Pharmaceuticals LLC | $18.97 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $16.74 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $13.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Chun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.